TrialCancer2020

Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).

Ronald C Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.